Analysis of the clinical application of anti-GD2 antibody therapy for high-risk neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in children.In recent years,the corresponding targeting drug an-ti-GD2 antibody has been designed according to a tumor-specific antigen in the form of a glycolipid antigen known as GD2.However,anti-GD2 antibody has been limited in clinical application due to high toxicity and side effects,less experience in domestic use,and expensive drug price.In this paper,we introduce the mechanism of action,efficacy,pretreatment dosing for adverse reactions and cost-effectiveness analysis of anti-GD2 antibody in order to provide a reference for clinical use of the drug.Anti-GD2 antibody can significantly improve the long-term survival quality of neuroblastoma patients,and the tolerance of patients to anti-GD2 antibody can be improved by pretreatment dosing,but the treatment cost of this drug is high,so only if its price is reduced,it is possible to become a cost-effective treatment option for children with high-risk neuroblastoma.
NETL
NSTL
万方数据
